HANXBIO-B buys back 27,700 H shares for HK$0.77 million, lifting treasury stock to over 1 million shares

Bulletin Express06-04

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a Next Day Disclosure Return showing an on-market repurchase of 27,700 H shares on 4 June 2026. The shares were bought at prices ranging from HK$27.20 to HK$28.00, translating to a volume-weighted average cost of HK$27.63 per share and a total consideration of HK$0.77 million.

Following the transaction, the company’s issued share capital (excluding treasury shares) declined by 0.02% to 135.21 million shares, while treasury shares rose to 1.01 million. Total issued shares, including treasury stock, remained unchanged at 136.22 million.

The repurchase was executed under the mandate approved on 12 February 2026, which authorises buybacks of up to 13.62 million shares. Cumulatively, HANXBIO-B has repurchased 1.01 million shares under this mandate, equivalent to 0.74% of the issued share count at the mandate date.

In accordance with Hong Kong Stock Exchange rules, the company is subject to a moratorium on issuing new shares or selling treasury shares until 4 July 2026. The board confirmed that the repurchase complied with all applicable listing rules and regulatory requirements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1135366156?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-04 20:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135366156","market":"hk","top_or_hot":-1,"title":"HANXBIO-B buys back 27,700 H shares for HK$0.77 million, lifting treasury stock to over 1 million shares","media":"Bulletin Express","content":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a Next Day Disclosure Return showing an on-market repurchase of 27,700 H shares on 4 June 2026. The shares were bought at prices ranging from HK$27.20 to HK$28.00, translating to a volume-weighted average cost of HK$27.63 per share and a total consideration of HK$0.77 million.</p>\n<p>Following the transaction, the company’s issued share capital (excluding treasury shares) declined by 0.02% to 135.21 million shares, while treasury shares rose to 1.01 million. Total issued shares, including treasury stock, remained unchanged at 136.22 million.</p>\n<p>The repurchase was executed under the mandate approved on 12 February 2026, which authorises buybacks of up to 13.62 million shares. Cumulatively, HANXBIO-B has repurchased 1.01 million shares under this mandate, equivalent to 0.74% of the issued share count at the mandate date.</p>\n<p>In accordance with Hong Kong Stock Exchange rules, the company is subject to a moratorium on issuing new shares or selling treasury shares until 4 July 2026. The board confirmed that the repurchase complied with all applicable listing rules and regulatory requirements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HANXBIO-B buys back 27,700 H shares for HK$0.77 million, lifting treasury stock to over 1 million shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHANXBIO-B buys back 27,700 H shares for HK$0.77 million, lifting treasury stock to over 1 million shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-04 20:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a Next Day Disclosure Return showing an on-market repurchase of 27,700 H shares on 4 June 2026. The shares were bought at prices ranging from HK$27.20 to HK$28.00, translating to a volume-weighted average cost of HK$27.63 per share and a total consideration of HK$0.77 million.</p>\n<p>Following the transaction, the company’s issued share capital (excluding treasury shares) declined by 0.02% to 135.21 million shares, while treasury shares rose to 1.01 million. Total issued shares, including treasury stock, remained unchanged at 136.22 million.</p>\n<p>The repurchase was executed under the mandate approved on 12 February 2026, which authorises buybacks of up to 13.62 million shares. Cumulatively, HANXBIO-B has repurchased 1.01 million shares under this mandate, equivalent to 0.74% of the issued share count at the mandate date.</p>\n<p>In accordance with Hong Kong Stock Exchange rules, the company is subject to a moratorium on issuing new shares or selling treasury shares until 4 July 2026. The board confirmed that the repurchase complied with all applicable listing rules and regulatory requirements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1135366156","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135366156","pubTimestamp":1780575799,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a Next Day Disclosure Return showing an on-market repurchase of 27,700 H shares on 4 June 2026. The shares were bought at prices...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"HANXBIO-B以77万港元回购27,700股H股，库存股增至逾100万股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a Next Day Disclosure Return showing an on-market repurchase of 27,700 H shares on 4 June 2026. The shares were bought at prices ranging from HK$27.20 to HK$28.00, translating to a volume-weighted average cost of HK$27.63 per share and a total consideration of HK$0.77 million.\nFollowing the transaction, the company’s issued share capital (excluding treasury shares) declined by 0.02% to 135.21 million shares, while treasury shares rose to 1.01 million. Total issued shares, including treasury stock, remained unchanged at 136.22 million.\nThe repurchase was executed under the mandate approved on 12 February 2026, which authorises buybacks of up to 13.62 million shares. Cumulatively, HANXBIO-B has repurchased 1.01 million shares under this mandate, equivalent to 0.74% of the issued share count at the mandate date.\nIn accordance with Hong Kong Stock Exchange rules, the company is subject to a moratorium on issuing new shares or selling treasury shares until 4 July 2026. The board confirmed that the repurchase complied with all applicable listing rules and regulatory requirements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1135366156","isCrawlerRequest":true}